Log in
Enquire now
Relay Therapeutics

Relay Therapeutics

Relay Therapeutics is a Cambridge, Massachusetts-based developer of an allosteric drug-discover platform that is intended to apply computational techniques to protein motion.

OverviewStructured DataIssuesContributors

Contents

relaytx.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Biomedical engineering
Biomedical engineering
0
Therapeutics
Therapeutics
Biology
Biology
Technology
Technology
Engineering
Engineering
Biotechnology
Biotechnology
Location
United States
United States
Cambridge, Massachusetts
Cambridge, Massachusetts
0
B2X
B2B
B2B
CEO
Sanjiv K. Patel
Sanjiv K. Patel
0
Founder
‌
Dorothee Kern
‌
David E. Shaw
‌
Matthew Jacobson (entrepreneur)
‌
Mark Murcko
AngelList URL
angel.co/company/relaytx
Pitchbook URL
pitchbook.com/profiles...166337-11
Legal Name
Relay Therapeutics, Inc.0
Legal classification
Corporation
Corporation
Date Incorporated
2015
Number of Employees (Ranges)
51 – 200
Email Address
info@relaytx.com0
bd@relaytx.com0
Phone Number
+161737088370
Number of Employees
2760
Full Address
399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE, MA, 021390
CIK Number
1,812,3640
Place of Incorporation
Delaware
Delaware
0
Investors
Biotechnology Value Fund (BVF Partners)
Biotechnology Value Fund (BVF Partners)
Tavistock Group
Tavistock Group
D. E. Shaw Research
D. E. Shaw Research
Foresite Capital
Foresite Capital
EcoR1 Capital
EcoR1 Capital
SoftBank Vision Fund
SoftBank Vision Fund
Casdin Capital
Casdin Capital
Perceptive Advisors
Perceptive Advisors
...
Founded Date
2016
Total Funding Amount (USD)
520,000,000
Latest Funding Round Date
2018
Stock Symbol
RLAY0
Exchange
Nasdaq
Nasdaq
Glassdoor ID
20275590
Board of Directors
Alexis Borisy
Alexis Borisy
0
‌
Douglas S. Ingram
0
‌
Laura Shawver
0
‌
Mark Murcko
0
Sanjiv K. Patel
Sanjiv K. Patel
0
‌
Linda A. Hill
0
‌
Jami Rubin
0
CFO
‌
Tom Catinazzo
0
Latest Funding Type
Series C
Series C
Patents Assigned (Count)
1
COO
‌
Imogen Pryce
0
Wellfound ID
relaytx
Country
United States
United States
0

Other attributes

Company Operating Status
Active
Latest Funding Round Amount (USD)
400,000,000
SIC Code
2,8360
Ticker Symbol
RLAY0

Relay Therapeutics is a precision oncology company that uses protein motion to develop cancer therapeutics. It was founded in 2016 by David E. Shaw, Dorothee Kern, Mark Murcko, and Matthew Jacobson. Relay Therapeutics started its initial public offering (IPO) on July 20th, 2020. Prior to that, the company raised funding until its Series C round, receiving financing from investors such as SoftBank, Foresite Capital, and Tavistock Group. Relay Therapeutics is headquartered in Cambridge, Massachusetts, United States.

Product and Service

Relay Therapeutics has its own proprietary drug development platform called Dynamo, which integrates long-timescale molecular dynamics simulations and machine learning together with room-temperature crystallography and cryoEM. Dynamo also utilizes an approach that Relay Therapeutics called as motion-based drug design (MBDD), which is a form of drug discovery process that allows for long-timescale simulations of protein dynamics. Through these techniques and existing genome data, Relay Therapeutics is able to develop compounds that target specific genes, with recently developed drugs aimed at SHP-2, FGFR2, and PI3Kα.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Relay Therapeutics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.